Why Most Feasibility Data Can’t Be Trusted

Overcoming Inflation and Inaccuracy with Real-World Precision in 2026

In the current landscape of 2026 clinical research, the “feasibility questionnaire” is often a source of fiction rather than fact. Traditionally, sites have felt pressured to over-promise on patient numbers to secure study awards, leading to a massive gap between projection and reality. At BioResearch Partner (BRP), we are challenging this status quo by addressing the crisis of clinical trial feasibility accuracy. We believe that a study built on inflated data is destined for delays, budget overruns, and failure. By replacing guesswork with verified, EHR-linked analytics and in-house diagnostics, BRP is providing global pharmaceutical sponsors with the one thing they need most: the truth.

Our mission in 2026 is to restore integrity to the startup phase by delivering feasibility data that is grounded in real-time patient metrics, not optimistic estimates.

The “Feasibility Gap”: Why Traditional Data Fails

The industry is waking up to the reality that standard feasibility metrics are often flawed. At BRP, we’ve identified why clinical trial feasibility accuracy has reached a breaking point:

The “Competitive Inflation” Trap: Sites often inflate their potential patient pool to win a contract, only to realize the protocol’s narrow inclusion/exclusion criteria exclude 90% of those candidates.
Outdated Database Mining: Many sites rely on “ghost” databases—patient lists that haven’t been updated in years and don’t reflect current health statuses or locations.
Protocol Complexity Blindness: Standard feasibility fails to account for the operational burden of 2026 protocols, which often require complex in-house imaging (MRI/CT) that many sites simply don’t have.
Lack of Real-Time Validation: Data is often “static,” failing to account for competing trials in the same region that are pulling from the same patient pool.
Human Bias: Without automated eSource integration, feasibility remains a manual, subjective process prone to human error and “best-case scenario” thinking.

BRP eliminates these risks by treating feasibility as a rigorous scientific exercise rather than a sales pitch.

How BRP Ensures Clinical Trial Feasibility Accuracy

Our 14 integrated locations in South Florida utilize a “Verified-First” framework to ensure our data is bulletproof before a single contract is signed:

Live EHR Integration: We don’t guess. We use advanced analytics to query our live database of over 570,000 active patients, applying specific protocol filters in real-time.
Verified Diagnostic Mapping: Since we house 1.5 Tesla MRI and 64-slice CT scans on-site, we can verify if our patients meet specific physiological criteria before we ever promise a number.
The “Double-Screen” Method: We conduct preliminary phone screenings during the feasibility stage to gauge actual patient interest and availability, not just medical eligibility.
Resource Capacity Modeling: We evaluate our coordinators’ current bandwidth and site equipment schedules to ensure we can actually execute the visits we are promising.
100% Digital Transparency: Sponsors are given access to anonymized data dashboards that show exactly where our numbers come from, providing a “consumer-grade” level of trust.

By bridging the gap between “paper potential” and “practical reality,” BRP sets a new global standard for site-selection reliability.

Who Benefits from High-Accuracy Feasibility?

When data is honest, every stakeholder in the 2026 research ecosystem operates with more confidence:

Clinical Operations Managers: Teams can design realistic timelines and avoid the “rescue site” scramble six months into the study.
Financial Controllers: Predictable enrollment leads to stable budgets, eliminating the waste of activating “non-performing” sites.
Medical Directors: Precision feasibility ensures the patient population accurately reflects the intended therapeutic target.
Principal Investigators: Our PIs can focus on high-quality medical oversight rather than constantly troubleshooting enrollment shortfalls.
Patients: Participants enter a study that is well-organized and properly staffed, ensuring a better experience and higher safety standards.

The BRP Advantage: Data You Can Take to the Bank

Choosing BioResearch Partner in 2026 means moving beyond the “hope-based” model of site selection:

Honest Projections: We would rather turn down a study that isn’t a fit than provide inaccurate data that causes a delay for the sponsor.
Speed to Activation: Because our feasibility data is already verified, we achieve site activation in under 30 days—well below the industry average.
High Conversion Rates: Our “Screen-to-Randomization” ratios are among the best in the industry because our pre-qualification is so rigorous.
Integrated Multi-Site Visibility: View the combined feasibility of 14 high-performing sites through a single, centralized BRP contact.
Advanced Technology Infrastructure: We invest in the latest eReg and eSource tools to ensure that once the trial starts, the data stays as accurate as the feasibility promised.

Revolutionizing South Florida’s Scientific Credibility

Miami is the hub of this transparency movement. BRP’s presence provides:

Deep Demographic Insights: We understand the unique health profiles of South Florida’s diverse communities, ensuring feasibility reflects local reality.
Verified Diversity Metrics: We provide sponsors with accurate data on underrepresented populations, helping them meet 2026’s modern diversity mandates.
Economic Impact: By providing reliable data, we attract high-value biotech investment to the region, creating a stable environment for scientific growth.

5 Questions to Ask Before Trusting a Feasibility Report

When was the database last updated? Static lists are often obsolete.
Does the site have the equipment on-site? External referrals add 50% more time to screening.
How many competing trials are currently active at the site? Overcrowded sites can’t deliver.
What percentage of the projection is pre-screened? Real-world interest is more important than a medical code.
Is the data electronically verified? Manual tallies are the leading cause of inaccuracy.

The BioResearch Partner Advantage

BRP stands apart as an industry leader because we:

Manage 100% of the feasibility and enrollment process in-house.
Prioritize scientific integrity over volume targets.
Invest in the technology needed to provide real-time, EHR-linked data.
Build long-term partnerships based on the rarest commodity in research: the truth.

Stop Guessing. Start Growing.

In 2026, clinical trial feasibility accuracy is the foundation of every successful drug launch. Partner with BioResearch Partner and build your next study on a foundation of facts.

📞 Call: 833-489-4978

🌐 Visit: www.bioresearchpartner.com

📩 Email: info@bioresearchpartner.com

Experience the future of medicine. Partner with BRP and ensure your clinical trial feasibility is accurate, verified, and future-ready.